aTyr Pharma, Inc. (NASDAQ: LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, immune-mediated diseases, in addition to a variety of cancers, recently declared operating consequences for the 3rd-quarter finished September 30, 2K17.
3rd-Quarter 2K17 Financial Results:
Research and development costs were $7.10M and $10.40M for the 3-months finished September 30, 2K17 and 2K16, respectively. The decline of $3.30M was due mainly to a $2.20M decline related to manufacturing costs incurred in support of Resolaris and a $1.80M decline as a result of the completion of clinical trials related to Resolaris. The decline was partially offset by a $0.30M incline related to discovery research hard works, a $0.20M incline in iMod.Fc research and non-clinical development costs and $0.20M incline related to ORCA research activities.
General and administrative costs remained relatively consistent at $3.70M as contrast to $3.50M for the 3-months finished September 30, 2K17 and 2K16, respectively.
Year-to-Date 2K17 Financial Results:
Research and development costs were $24.80M and $33.70M for the 9-months finished September 30, 2K17 and 2K16, respectively. The decline of $8.90M was due mainly to a $6.50M decline related to manufacturing costs incurred in support of Resolaris, a $4.00M decline as a result of the completion of clinical trials related to Resolaris, a $0.30M decline in discovery projects, and a $0.30M decline in non-cash stock-based compensation. The decline was partially offset by a $1.10M incline related to research and non-clinical development costs incurred for iMod.Fc, and a $1.10M incline related to ORCA research activities.
General and administrative costs were $11.20M and $11.70M for the 9-months finished September 30, 2K17 and 2K16, respectively. The decline of $0.50M was mainly because of a decline in professional fees.
Financial Guidance:
As of September 30, 2K17, aTyr had $90.40M in cash, cash equivalents and investments and 41.10M shares of common stock outstanding on an if-converted basis (includes 29.70M shares of common stock and 11.40M shares of common stock if converted from Class X Preferred stock).
aTyr anticipates that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into the middle of 2k19.
